1
2
3
4
5
6
2
3
4
5
6
Published In
Archives of Rheumatology
Volume: 35 Issue: 3, September 2020
Pages: 366-375
History
Published Online: September 30, 2020
This work is licensed under a Creative Commons Attribution 4.0 International License.
Kyung-Ann LEE
Department of Internal Medicine, Soonchunhyang University School of Medicine, Seoul, South Korea
Bo Young KIM
Department of Internal Medicine, Gangneung Asan Hospital, Gangneung, South Korea
Sung Jae CHOI
Department of Internal Medicine, Korea University, Ansan, South Korea
Seong-Kyu KIM
Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea
Sang-Hyon KIM
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea
Hyun-Sook KIM
Department of Internal Medicine, Soonchunhyang University School of Medicine, Seoul, South Korea
Kyung-Ann LEE, Bo Young KIM, Sung Jae CHOI, Seong-Kyu KIM, Sang-Hyon KIM, & Hyun-Sook KIM. (2020). A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study. Archives of Rheumatology, 35(3), 366–375. https://doi.org/10.46497/ArchRheumatol.2020.7771
Abstract
Objectives: This study aims to assess the efficacy and safety of mycophenolate mofetil (MMF) on lung function and skin thickness in Korean patients with systemic sclerosis-interstitial lung disease (SSc-ILD) in a real-world setting.
Patients and methods: This retrospective, medical chart-based study was performed at four centers in South Korea and included 34 patients (2 males, 32 females; median age 50.5 years; range, 25 to 72 years) with SSc-ILD. We investigated changes in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), and modified Rodnan skin score (mRSS) according to MMF treatment for 24 months.
Results: The mean dose and treatment duration of MMF were 1,338.2±439.0 mg/day and 13.1±9.3 months, respectively. Although FVC decreased significantly at 15 months, FVC and DLCO did not change significantly during treatment with MMF. Median mRSS decreased significantly from 17.5 (2-40) to 10.5 (2-40) units (p<0.0001). Thirteen patients (38.24%) discontinued treatment with MMF [treatment duration 8.00 (3.0-24.0) months]; the predominant cause of discontinuation was of economic nature (46.15%). No serious adverse events were reported.
Conclusion: This real-world based study supports the role of MMF in the stabilization of lung function and the improvement in skin thickness with an acceptable safety profile in patients with SSc. Economic burden is the main cause of discontinued treatment with MMF.
Similar Articles
Similar Articles
- Mahmut ALPAYCI, Colchicine as a Possible Alternative Treatment for Chronic Recurrent Multifocal Osteomyelitis , Archives of Rheumatology: Vol. 28 No. 4 (2013): The Archives of Rheumatology
- Sertaç KETENCİ, Ender SALBAŞ, Are These Truly Rheumatoid Arthritis or Antisynthetase Syndrome Cases? , Archives of Rheumatology: Vol. 34 No. 3 (2019): The Archives of Rheumatology
- Hakan Terekeci, Cihan Top, Pregnancy and Rheumatic Diseases , Archives of Rheumatology: Vol. 23 No. 4 (2008): The Archives of Rheumatology
- Aslı ASLAN, Güldane KOTUROĞLU, Betül SÖZERİ, Zafer KURUGÖL, Systemic Scleroderma in Childhood: A Case Report , Archives of Rheumatology: Vol. 29 No. 3 (2014): The Archives of Rheumatology
- Belde Kasap, Alper Soylu, Mehmet Türkmen, Salih Kavukçu, Juvenile Scleroderma: Apropos of Two Cases , Archives of Rheumatology: Vol. 22 No. 4 (2007): The Archives of Rheumatology
- Serdar Kaymaz, Murat Kavas, Aydın Demiray, Uğur Karasu, Veli Çobankara, Sibel Boğa, Investigation of the relationship between interferon-gamma receptor 1-56C/T gene polymorphism and genetic susceptibility to lung sarcoidosis: A cross-sectional study , Archives of Rheumatology: Vol. 38 No. 1 (2023): The Archives of Rheumatology
- Mi-Hye KWON, Chung-Il JOUNG, Adult-onset Still’s Disease Associated with Scrub Typhus , Archives of Rheumatology: Vol. 30 No. 3 (2015): The Archives of Rheumatology
- Hong Chen*, Jun Tang*, Juhua Liang, Dan Huang, Chunfeng Pan, Sha Liu, Xiuri Du, Liju Tao, Clinical association study on the matrix metalloproteinase expression in the serum of patients with connective tissue disease complicated with interstitial lung disease , Archives of Rheumatology: Vol. 38 No. 3 (2023): The Archives of Rheumatology
- Dilara Bulut Gökten, Fatma Yümün Kavak, Rıdvan Mercan, Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus? , Archives of Rheumatology: Vol. 39 No. 3 (2024): The Archives of Rheumatology
- Agata SEBASTIAN, Aleksandra BUTRYM, Maria MISTERSKA SKÓRA, Arkadiusz CHLEBICKI, Grzegorz MAZUR, Piotr WILAND, Systemic Lupus Erythematosus Induced by Autoimmune/ Inflammatory Syndrome Induced by Adjuvants. Is it Possible? Long-Term Follow-up and Literature Review , Archives of Rheumatology: Vol. 33 No. 2 (2018): The Archives of Rheumatology
<< < 3 4 5 6 7 8 9 10 11 12 > >>
You may also start an advanced similarity search for this article.
Article Info
Published In
Journal
Archives of Rheumatology
Volume / Issue
Vol. 35 No. 3 (2020): The Archives of Rheumatology
Pages
366-375
History
Published Online
September 30, 2020
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Affiliations
1
Kyung-Ann LEE
Department of Internal Medicine, Soonchunhyang University School of Medicine, Seoul, South Korea
2
Bo Young KIM
Department of Internal Medicine, Gangneung Asan Hospital, Gangneung, South Korea
3
Sung Jae CHOI
Department of Internal Medicine, Korea University, Ansan, South Korea
4
Seong-Kyu KIM
Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea
5
Sang-Hyon KIM
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea
6
Hyun-Sook KIM
Department of Internal Medicine, Soonchunhyang University School of Medicine, Seoul, South Korea
Cite this Article
Kyung-Ann LEE, Bo Young KIM, Sung Jae CHOI, Seong-Kyu KIM, Sang-Hyon KIM, & Hyun-Sook KIM. (2020). A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study. Archives of Rheumatology, 35(3), 366–375. https://doi.org/10.46497/ArchRheumatol.2020.7771
Outlines